These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28475384)

  • 21. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical therapy of inflammatory bowel disease for the 21st century.
    Robinson M
    Eur J Surg Suppl; 1998; (582):90-8. PubMed ID: 10029372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary Management of Ulcerative Colitis.
    Vanga R; Long MD
    Curr Gastroenterol Rep; 2018 Mar; 20(3):12. PubMed ID: 29589185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of biologics in the treatment of patients with inflammatory bowel disease.
    Selinger CP; Carbery I; Al-Asiry J
    Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.
    Singh S; Allegretti JR; Siddique SM; Terdiman JP
    Gastroenterology; 2020 Apr; 158(5):1465-1496.e17. PubMed ID: 31945351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conventional medical management of inflammatory bowel disease.
    Burger D; Travis S
    Gastroenterology; 2011 May; 140(6):1827-1837.e2. PubMed ID: 21530749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drugs for inflammatory bowel disease.
    Med Lett Drugs Ther; 2018 Jul; 60(1550):107-114. PubMed ID: 30036352
    [No Abstract]   [Full Text] [Related]  

  • 28. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
    Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
    Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis.
    Jackson B; De Cruz P
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1079-1100. PubMed ID: 30284911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.
    Lawrance IC
    Expert Opin Investig Drugs; 2015 Jun; 24(6):761-8. PubMed ID: 25719407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current therapeutic approaches in inflammatory bowel disease.
    Sohrabpour AA; Malekzadeh R; Keshavarzian A
    Curr Pharm Des; 2010; 16(33):3668-83. PubMed ID: 21128898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The state of the art in the management of inflammatory bowel disease.
    Hanauer SB; Present DH
    Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of steroid-resistant inflammatory bowel disease.
    Manz M; Vavricka SR; Wanner R; Lakatos PL; Rogler G; Frei P; Safroneeva E; Schoepfer AM
    Digestion; 2012; 86 Suppl 1():11-5. PubMed ID: 23051721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of drugs used for the treatment of Crohn's disease.
    Pudipeddi A; Kariyawasam V; Haifer C; Baraty B; Paramsothy S; Leong RW
    Expert Opin Drug Saf; 2019 May; 18(5):357-367. PubMed ID: 31026401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Medical therapy of inflammatory bowel diseases: ulcerative colitis].
    Lakatos L; Lakatos PL
    Orv Hetil; 2007 Jun; 148(25):1163-70. PubMed ID: 17573252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting TNF-α for the treatment of inflammatory bowel disease.
    Billiet T; Rutgeerts P; Ferrante M; Van Assche G; Vermeire S
    Expert Opin Biol Ther; 2014 Jan; 14(1):75-101. PubMed ID: 24206084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.